JP2016523919A - Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 - Google Patents

Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 Download PDF

Info

Publication number
JP2016523919A
JP2016523919A JP2016524268A JP2016524268A JP2016523919A JP 2016523919 A JP2016523919 A JP 2016523919A JP 2016524268 A JP2016524268 A JP 2016524268A JP 2016524268 A JP2016524268 A JP 2016524268A JP 2016523919 A JP2016523919 A JP 2016523919A
Authority
JP
Japan
Prior art keywords
amino acids
chimeric molecule
vwf
fviii
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016524268A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016523919A5 (enExample
Inventor
エクタ セス チャブラ，
エクタ セス チャブラ，
ジョン クルマン，
ジョン クルマン，
トンヤオ リウ，
トンヤオ リウ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2016523919A publication Critical patent/JP2016523919A/ja
Publication of JP2016523919A5 publication Critical patent/JP2016523919A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016524268A 2013-06-28 2014-06-27 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用 Pending JP2016523919A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361840872P 2013-06-28 2013-06-28
US61/840,872 2013-06-28
PCT/US2014/044731 WO2014210558A1 (en) 2013-06-28 2014-06-27 Thrombin cleavable linker with xten and its uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018195860A Division JP2019010124A (ja) 2013-06-28 2018-10-17 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用

Publications (2)

Publication Number Publication Date
JP2016523919A true JP2016523919A (ja) 2016-08-12
JP2016523919A5 JP2016523919A5 (enExample) 2017-08-10

Family

ID=52142742

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2016524268A Pending JP2016523919A (ja) 2013-06-28 2014-06-27 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
JP2018195860A Pending JP2019010124A (ja) 2013-06-28 2018-10-17 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
JP2021018123A Active JP7005800B2 (ja) 2013-06-28 2021-02-08 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
JP2021163956A Active JP7297837B2 (ja) 2013-06-28 2021-10-05 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
JP2023097660A Active JP7623426B2 (ja) 2013-06-28 2023-06-14 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
JP2025005420A Pending JP2025061316A (ja) 2013-06-28 2025-01-15 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2018195860A Pending JP2019010124A (ja) 2013-06-28 2018-10-17 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
JP2021018123A Active JP7005800B2 (ja) 2013-06-28 2021-02-08 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
JP2021163956A Active JP7297837B2 (ja) 2013-06-28 2021-10-05 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
JP2023097660A Active JP7623426B2 (ja) 2013-06-28 2023-06-14 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
JP2025005420A Pending JP2025061316A (ja) 2013-06-28 2025-01-15 Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用

Country Status (17)

Country Link
US (3) US20160251408A1 (enExample)
EP (2) EP3013358A4 (enExample)
JP (6) JP2016523919A (enExample)
KR (4) KR102666819B1 (enExample)
CN (3) CN113831415A (enExample)
AU (3) AU2014302100B2 (enExample)
CA (1) CA2913078A1 (enExample)
CL (1) CL2015003710A1 (enExample)
EA (1) EA201592022A1 (enExample)
HK (1) HK1223302A1 (enExample)
IL (3) IL242436B (enExample)
MX (1) MX2015016567A (enExample)
NZ (1) NZ713904A (enExample)
PH (1) PH12015502614A1 (enExample)
SG (3) SG10201710616XA (enExample)
TW (3) TWI770467B (enExample)
WO (1) WO2014210558A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503509A (ja) * 2014-01-10 2017-02-02 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇ 第ｖｉｉｉ因子キメラタンパク質及びその使用
US12030925B2 (en) 2018-05-18 2024-07-09 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
RS59670B1 (sr) 2012-01-12 2020-01-31 Bioverativ Therapeutics Inc Himerni polipeptidi faktora viii i njihove upotrebe
PT2814840T (pt) 2012-02-15 2020-01-28 Bioverativ Therapeutics Inc Composições de fator viii e métodos de produção e utilização das mesmas
HUE043537T2 (hu) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Rekombináns VIII faktor fehérjék
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
RS59876B1 (sr) 2012-07-11 2020-03-31 Bioverativ Therapeutics Inc Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
DK3265489T3 (da) * 2015-03-06 2019-07-15 CSL Behring Lengnau AG Forbindelser til forbedring af halveringstiden af von willebrand faktor
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
CN109790529A (zh) * 2016-06-24 2019-05-21 财团法人牧岩生命科学研究所 包含FVIII和vWF因子的嵌合蛋白及其用途
ES2869339T3 (es) * 2016-11-11 2021-10-25 CSL Behring Lengnau AG Polipéptidos del factor von Willebrand truncados para el tratamiento de la hemofilia
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076484A1 (en) * 2003-02-27 2004-09-10 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
US20080146782A1 (en) * 2006-10-04 2008-06-19 Neose Technologies, Inc. Glycerol linked pegylated sugars and glycopeptides
JP2009505964A (ja) * 2005-08-04 2009-02-12 ヘモスタティクス リミテッド 人工血小板
WO2011069164A2 (en) * 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
JP2011525363A (ja) * 2008-06-24 2011-09-22 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 延長されたインビボ半減期を有する第ｖｉｉｉ因子、フォン・ヴィレブランド因子又はそれらの複合体
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
JP2013510581A (ja) * 2009-11-13 2013-03-28 グリフオルス・セラピユーテイクス・インコーポレーテツド フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
DE3683980D1 (de) 1985-04-12 1992-04-02 Genetics Inst Neue prokoagulierungsproteine.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
JP2525022B2 (ja) 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド ▲ＶＩＩＩ▼：ｃ因子型タンパク質の改良生産方法
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) * 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2378473A1 (en) * 1999-07-23 2001-02-01 The Regents Of The University Of California Modulation of platelet activation
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
ES2256234T3 (es) 2000-05-16 2006-07-16 Lipoxen Technologies Limited Derivatizacion de proteinas en solucion acuosa.
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002316574B2 (en) 2002-03-15 2008-05-01 Brandeis University Central airway administration for systemic delivery of therapeutics
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
AU2004215912B2 (en) 2003-02-26 2009-03-26 Nektar Therapeutics Polymer-factor VIII moiety conjugates
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
MX2008001865A (es) 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
JP2010503396A (ja) 2006-09-14 2010-02-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合タンパク質
EP2097096B1 (en) * 2006-12-22 2017-05-31 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
KR101631323B1 (ko) 2007-06-21 2016-06-17 엑스엘-프로테인 게엠베하 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질
WO2009062100A1 (en) * 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
JP2012510060A (ja) * 2008-11-24 2012-04-26 バイエル・ヘルスケア・エルエルシー シリカをベースとする活性化部分トロンボプラスチン時間アッセイにおけるｐｅｇ化血液凝固因子の活性の測定方法
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010091122A1 (en) * 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US20120142593A1 (en) * 2009-03-24 2012-06-07 Bayer Healthcare Llc Factor VIII Variants and Methods of Use
NZ621868A (en) 2009-06-08 2015-10-30 Amunix Operating Inc Growth hormone polypeptides and methods of making and using same
EP2440228B8 (en) 2009-06-08 2023-02-22 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
EP2470559B1 (en) * 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
JP5544219B2 (ja) * 2009-09-24 2014-07-09 富士フイルム株式会社 内視鏡システム
US20110312881A1 (en) * 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
DK2591099T3 (da) 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
RS59670B1 (sr) * 2012-01-12 2020-01-31 Bioverativ Therapeutics Inc Himerni polipeptidi faktora viii i njihove upotrebe
HUE043537T2 (hu) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Rekombináns VIII faktor fehérjék
PT2814840T (pt) 2012-02-15 2020-01-28 Bioverativ Therapeutics Inc Composições de fator viii e métodos de produção e utilização das mesmas
WO2013083858A1 (en) * 2012-04-24 2013-06-13 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
RS59876B1 (sr) * 2012-07-11 2020-03-31 Bioverativ Therapeutics Inc Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
DK2796145T3 (da) * 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
HK1223303A1 (zh) * 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 凝血酶可裂解连接子
EP3091997B1 (en) * 2014-01-10 2022-07-06 Bioverativ Therapeutics Inc. Factor viii chimeric proteins and uses thereof
BR112020022164A2 (pt) * 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076484A1 (en) * 2003-02-27 2004-09-10 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
JP2009505964A (ja) * 2005-08-04 2009-02-12 ヘモスタティクス リミテッド 人工血小板
US20080146782A1 (en) * 2006-10-04 2008-06-19 Neose Technologies, Inc. Glycerol linked pegylated sugars and glycopeptides
JP2011525363A (ja) * 2008-06-24 2011-09-22 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 延長されたインビボ半減期を有する第ｖｉｉｉ因子、フォン・ヴィレブランド因子又はそれらの複合体
JP2013510581A (ja) * 2009-11-13 2013-03-28 グリフオルス・セラピユーテイクス・インコーポレーテツド フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用
WO2011069164A2 (en) * 2009-12-06 2011-06-09 Biogen Idec Ma Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
JP2013512678A (ja) * 2009-12-06 2013-04-18 バイオジェン アイデック ヘモフィリア インコーポレイテッド 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
血栓止血誌, vol. 23, JPN7018001583, 2012, pages 47 - 50, ISSN: 0004001717 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017503509A (ja) * 2014-01-10 2017-02-02 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇ 第ｖｉｉｉ因子キメラタンパク質及びその使用
JP2020156520A (ja) * 2014-01-10 2020-10-01 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子キメラタンパク質及びその使用
JP2021065240A (ja) * 2014-01-10 2021-04-30 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子キメラタンパク質及びその使用
US11192936B2 (en) 2014-01-10 2021-12-07 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
JP7104194B2 (ja) 2014-01-10 2022-07-20 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子キメラタンパク質及びその使用
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US12030925B2 (en) 2018-05-18 2024-07-09 Bioverativ Therapeutics Inc. Methods of treating hemophilia A

Also Published As

Publication number Publication date
JP2022000053A (ja) 2022-01-04
CN113831415A (zh) 2021-12-24
CN105392495A (zh) 2016-03-09
KR20240023705A (ko) 2024-02-22
MX2015016567A (es) 2016-03-31
WO2014210558A1 (en) 2014-12-31
EP4368194A3 (en) 2024-07-31
IL266462A (en) 2019-06-30
SG10201710616XA (en) 2018-02-27
AU2023219840A1 (en) 2023-09-14
JP2025061316A (ja) 2025-04-10
CL2015003710A1 (es) 2016-08-26
IL297611B1 (en) 2025-07-01
KR20230007555A (ko) 2023-01-12
BR112015031194A2 (pt) 2017-09-19
HK1223302A1 (zh) 2017-07-28
KR20240148954A (ko) 2024-10-11
TWI844042B (zh) 2024-06-01
JP2019010124A (ja) 2019-01-24
KR102714760B9 (ko) 2025-09-15
US20160251408A1 (en) 2016-09-01
IL242436B (en) 2019-05-30
JP7297837B2 (ja) 2023-06-26
TW202045535A (zh) 2020-12-16
PH12015502614A1 (en) 2016-02-29
US20240083975A1 (en) 2024-03-14
KR102666819B1 (ko) 2024-05-23
IL266462B2 (en) 2023-04-01
US20220106383A1 (en) 2022-04-07
SG11201509313PA (en) 2016-01-28
EP3013358A4 (en) 2017-03-22
JP2021072853A (ja) 2021-05-13
JP7623426B2 (ja) 2025-01-28
IL297611B2 (en) 2025-11-01
TW201514204A (zh) 2015-04-16
KR20160023654A (ko) 2016-03-03
JP2023107932A (ja) 2023-08-03
CN113817069A (zh) 2021-12-21
CA2913078A1 (en) 2014-12-31
TWI716340B (zh) 2021-01-21
AU2014302100B2 (en) 2020-02-13
NZ713904A (en) 2022-02-25
IL266462B (en) 2022-12-01
JP7005800B2 (ja) 2022-02-10
AU2020203063A1 (en) 2020-05-28
AU2020203063B2 (en) 2023-05-25
SG10201913738YA (en) 2020-03-30
IL297611A (en) 2022-12-01
EP4368194A2 (en) 2024-05-15
KR102714760B1 (ko) 2024-10-11
KR102865153B1 (ko) 2025-09-29
EA201592022A1 (ru) 2016-05-31
TW202313672A (zh) 2023-04-01
EP3013358A1 (en) 2016-05-04
AU2014302100A1 (en) 2015-11-26
TWI770467B (zh) 2022-07-11

Similar Documents

Publication Publication Date Title
JP7623426B2 (ja) Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
JP7682968B2 (ja) ＸＴＥＮおよびｖｏｎ Ｗｉｌｌｅｂｒａｎｄ因子タンパク質を有する第ＶＩＩＩ因子の複合体、および、その使用
JP7217630B2 (ja) 最適化第ｖｉｉｉ因子遺伝子
KR102659212B1 (ko) 인자 ix 융합 단백질 및 이의 제조 방법 및 사용 방법
JP6749836B2 (ja) 第ｖｉｉｉ因子キメラタンパク質及びその使用
TWI727187B (zh) 嵌合因子viii多肽及其用途
TW201542596A (zh) 凝血酶可裂解連接子
HK40111404A (en) Thrombin cleavable linker with xten and its uses thereof
BR112015031194B1 (pt) Molécula quimérica, composição farmacêutica, e uso dos anteriores
HK40099494A (en) Factor viii complex with xten and von willebrand factor protein, and uses thereof
HK1211228B (en) Factor viii complex with xten and von willebrand factor protein, and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170627

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180425

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200129